Governor Josh Stein marks strengthening North Carolina-Ireland trade relationship at Uniphar facility visit
September 16, 2026 |
The event speaker panel, from left to right: Brian Kiefel, Ireland Site Leader & CTO, Honeywell; Christopher Chung, Chief Executive Officer, EDPNC; Tom Scrivener, Group COO, Bank of America; Ambassador of Ireland to the United States Geraldine Byrne Nason; Ger Rabbitte, CEO, Uniphar; Kevin Sherry, Executive Director, Enterprise Ireland; Deirdre MacCarthy, Chief Legal Officer, Wayflyer; and Seamus Egan, Commercial Director, Uniphar.
Industry representatives, economic development leaders and senior executives from Uniphar plc gathered at the company’s new 330,000 sq. ft. Greenogue G2 facility in Dublin last week to welcome North Carolina Governor Josh Stein during his visit to Ireland.
The Governor’s visit reflects the growing economic relationship between North Carolina and Ireland with Irish companies employing around 7,000 people across the state, while North Carolina exported nearly $890 million in goods to Ireland last year. Uniphar’s expanding investment in North Carolina includes its 65,000 sq. ft. pharmaceutical and life sciences logistics hub in Raleigh, supporting the movement of healthcare products and services throughout the United States (US) and worldwide.
Josh Stein, North Carolina Governor meets Ger Rabbitte, CEO, Uniphar; Kevin Sherry, Executive Director, Enterprise Ireland and Brian O’Shaughnessy, CCO, Uniphar.
Welcoming Governor Stein, Ger Rabbette, Chief Executive Officer of Uniphar plc, highlighted the strategic importance of the facility as well as the company’s growing presence in the US.
“Greenogue is one of the most sophisticated pharmaceutical distribution facilities in Europe, but it also represents a broader vision for building a more connected global healthcare infrastructure across Ireland, the UK, Europe and the United States. North Carolina was a natural choice for our US East Coast hub, providing access to one of the country’s most dynamic life sciences ecosystems and enabling us to support customers across the region. We are proud to contribute to the strong and growing economic relationship between Ireland and the United States, and particularly the partnership between Ireland and North Carolina.”
North Carolina is recognized as one of the leading life sciences centers in the United States, with a thriving pharmaceutical, biotechnology and medical technology sector. Uniphar’s 65,000 sq. ft. Raleigh distribution hub, located in North Carolina’s Research Triangle region, forms a key component of its global logistics network, connecting North American customers with the company’s wider operations across Europe, Asia-Pacific and the Middle East.
The Greenogue facility is Uniphar’s new 330,000 sq. ft. LEED Gold-certified distribution hub and one of the most advanced pharmaceutical logistics facilities in Europe. Featuring state-of-the-art automation and advanced storage and picking technologies, it forms part of Uniphar’s wider international infrastructure program to strengthen healthcare supply chains through a network of strategic distribution centers across Ireland, the UK, Europe and the United States.
From these facilities, Uniphar supports more than 200 multinational pharmaceutical and medical technology manufacturers, delivering healthcare products to over 160 countries worldwide.
Governor Stein praised both the scale of Uniphar’s investment in Ireland and the company’s commitment to North Carolina:
“Uniphar’s investment in Raleigh reflects the strong and growing partnership between North Carolina and Ireland. Its East Coast hub has further strengthened our state’s world-class life sciences sector and created new opportunities for trade and collaboration. Uniphar is one of nearly 50 Irish companies employing more than 7,000 North Carolinians, making Ireland an important part of North Carolina’s success story.”
ENDS
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
Governor Josh Stein marks strengthening North Carolina-Ireland trade relationship at Uniphar facility visit
The event speaker panel, from left to right: Brian Kiefel, Ireland Site Leader & CTO, Honeywell; Christopher Chung, Chief Executive Officer, EDPNC; Tom Scrivener, Group COO, Bank of America; Ambassador…
J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology…
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing…
Strategies to enhance the provider and patient EAP experience
Expanded access programs (EAPs) play a multifaceted role in the drug development life cycle, serving as a critical bridge between clinical trials and commercial availability.
Uniphar | Clinical merges with BMclinical to strengthen global clinical trial services
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide. As part of Uniphar’s global platform supporting…
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
– New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. – Mike Ebhardt is appointed President of Uniphar Pharma…
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and…
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe…
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer…
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of…
- 1
- 2